DE3852761T3 - Saponin-hilfsmittel. - Google Patents

Saponin-hilfsmittel.

Info

Publication number
DE3852761T3
DE3852761T3 DE3852761T DE3852761T DE3852761T3 DE 3852761 T3 DE3852761 T3 DE 3852761T3 DE 3852761 T DE3852761 T DE 3852761T DE 3852761 T DE3852761 T DE 3852761T DE 3852761 T3 DE3852761 T3 DE 3852761T3
Authority
DE
Germany
Prior art keywords
saponine
tools
saponins
disclosed
substantially pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3852761T
Other languages
English (en)
Other versions
DE3852761D1 (de
DE3852761T2 (de
Inventor
Charlotte Kensil
Dante Marciani
Gerald Beltz
Chung-Ho Hung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agenus Inc
Original Assignee
Aquila Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21996520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3852761(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aquila Biopharmaceuticals Inc filed Critical Aquila Biopharmaceuticals Inc
Publication of DE3852761D1 publication Critical patent/DE3852761D1/de
Publication of DE3852761T2 publication Critical patent/DE3852761T2/de
Application granted granted Critical
Publication of DE3852761T3 publication Critical patent/DE3852761T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005—Glycosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
DE3852761T 1987-05-29 1988-05-31 Saponin-hilfsmittel. Expired - Lifetime DE3852761T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5522987A 1987-05-29 1987-05-29
PCT/US1988/001842 WO1988009336A1 (en) 1987-05-29 1988-05-31 Saponin adjuvant

Publications (3)

Publication Number Publication Date
DE3852761D1 DE3852761D1 (de) 1995-02-23
DE3852761T2 DE3852761T2 (de) 1995-09-07
DE3852761T3 true DE3852761T3 (de) 2000-06-21

Family

ID=21996520

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3852761T Expired - Lifetime DE3852761T3 (de) 1987-05-29 1988-05-31 Saponin-hilfsmittel.

Country Status (8)

Country Link
EP (1) EP0362279B2 (de)
JP (1) JP2731563B2 (de)
AT (1) ATE116993T1 (de)
AU (1) AU616670B2 (de)
CA (1) CA1331443C (de)
DE (1) DE3852761T3 (de)
DK (1) DK175739B1 (de)
WO (1) WO1988009336A1 (de)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
GB9202933D0 (en) * 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5273965A (en) * 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
NL9301690A (nl) * 1993-08-12 1995-04-18 Seed Capital Investments Verbindingen met adjuvans-activiteit.
WO1995009179A1 (en) * 1993-09-30 1995-04-06 Seed Capital Investments (Sci) B.V. Compounds with adjuvant activity
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5597807A (en) * 1994-08-01 1997-01-28 University Of Saskatchewan Quinoa saponin compositions and methods of use
US5688772A (en) * 1994-08-01 1997-11-18 University Of Saskatchewan Quinoa saponin compositions and methods of use
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2762787B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
JP2002505665A (ja) * 1997-04-30 2002-02-19 メリュー・オラバックス Ｔｈ１型アジュバントを含有する抗ヘリコバクターワクチン組成物
FR2762788B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter pour usage par voie systemique sous-diaphragmatique
WO1998056415A1 (en) * 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
US6241995B1 (en) 1997-08-08 2001-06-05 University Of Saskatchewan Polygala senega compositions and methods of use
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
ES2228497T3 (es) 1999-04-19 2005-04-16 Glaxosmithkline Biologicals S.A. Composicion adyuvante que comprende saponina y un oligonucleotido inmunoestimulante.
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AU780444B2 (en) 1999-05-03 2005-03-24 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1227837B1 (de) 1999-10-22 2008-05-21 Aventis Pasteur Limited Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
ES2276788T3 (es) 2000-05-10 2007-07-01 Sanofi Pasteur Limited Polipeptidos inmunogenos codificados por minigenes mage y sus utilizaciones.
PT2266603E (pt) 2000-10-18 2012-11-02 Glaxosmithkline Biolog Sa Vacinas tumorais
CA2438942A1 (en) 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
EP1569515A4 (de) 2002-10-23 2006-04-26 Glaxosmithkline Biolog Sa Malaria-impfverfahren
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
CA2565500A1 (en) 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
CN101107009B (zh) 2005-01-20 2014-08-06 伊斯克诺瓦公司 包含纤连蛋白结合蛋白或纤连蛋白结合肽的疫苗组合物
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
PL1877426T3 (pl) 2005-04-29 2012-10-31 Glaxosmithkline Biologicals Sa Sposób profilaktyki lub leczenia zakażenia M. tuberculosis
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EP1989308B1 (de) 2006-03-03 2017-05-31 ProMIS Neurosciences Inc. Verfahren und zusammensetzungen zum behandeln und erkennen von missgefaltetem sod1-herbeigeführte erkrankungen
WO2008030154A1 (en) * 2006-09-08 2008-03-13 Hemocue Ab Haemolysing agent
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2068918B1 (de) 2006-09-26 2012-05-02 Infectious Disease Research Institute Impfstoffzusammensetzung mit einem synthetischen adjuvans
EA021391B1 (ru) 2007-03-02 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор
BRPI0815199A2 (pt) 2007-08-13 2015-03-31 Glaxosmithkline Biolog Sa Uso de um antígeno derivado da proteína circunsporozóite de plasmodium falciparum
JP5501969B2 (ja) 2007-09-11 2014-05-28 ユニバーシティ オブ グェルフ クロストリジウム・ディフィシル由来の多糖免疫原
JP2011500730A (ja) 2007-10-26 2011-01-06 ガバニング カウンセル オブ ザ ユニバーシティ オブ トロント Ｔｉｍ−３を用いた治療および診断方法
EP2062594A1 (de) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Impfstoff und immunogene Zusammensetzung gegen den Blauzungenvirus, Verfahren zu deren Verwendung und Verfahren zu deren Herstellung
CN101952321B (zh) 2007-12-24 2016-05-11 葛兰素史密斯克莱生物公司 重组rsv抗原
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
AU2009296458A1 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
WO2010094663A1 (en) 2009-02-17 2010-08-26 Glaxosmithkline Biologicals S.A. Inactivated dengue virus vaccine with aluminium-free adjuvant
EP2437753B1 (de) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetische glucopyranosyl-lipid-adjuvanzien und impfstoffzusammensetzungen die diese enthalten
US20100316673A1 (en) 2009-06-16 2010-12-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
SG176807A1 (en) 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
DK2445526T3 (en) 2009-06-24 2016-06-27 Glaxosmithkline Biologicals Sa Recombinant RSV antigens.
EP3178490B1 (de) 2009-07-15 2022-04-20 GlaxoSmithKline Biologicals S.A. Rsv-f-proteinzusammensetzungen und verfahren zu ihrer herstellung
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
MY157607A (en) * 2009-09-10 2016-06-30 Merial Inc New vaccine formulations comprising saponin-containing adjuvants
WO2011034950A1 (en) 2009-09-16 2011-03-24 Vaxart, Inc. Immunization strategy to prevent h1n1 infection
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
KR102143105B1 (ko) 2010-07-23 2020-08-11 이스코노바 에이비 인플루엔자 백신
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
KR20130140009A (ko) 2010-10-15 2013-12-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 사이토메갈로바이러스 ｇｂ 항원
US9352030B2 (en) 2010-12-14 2016-05-31 Glaxosmithkline Biologicals, S.A. Mycobacterium antigenic composition
MD4177C1 (ro) * 2011-01-14 2013-02-28 Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова Metodă de vaccinare contra hepatitei virale B a persoanelor imunocompromise
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
US9044420B2 (en) 2011-04-08 2015-06-02 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
DK2758432T3 (da) 2011-09-16 2019-06-03 Ucb Biopharma Sprl Neutraliserende antistoffer mod hovedtoksinerne TcdA og TcdB fra Clostridium difficile
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
CN108864291A (zh) 2011-11-23 2018-11-23 拜奥文斯瑞有限公司 重组蛋白及其治疗用途
CA2856722C (en) 2011-11-30 2022-11-22 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
US11510875B2 (en) 2012-02-07 2022-11-29 Access To Advanced Health Institute Adjuvant formulations comprising TLR4 agonists and methods of using the same
EP3388835B1 (de) 2012-05-16 2020-04-01 Immune Design Corp. Impfstoffe gegen hsv-2
EP2666785A1 (de) 2012-05-23 2013-11-27 Affiris AG Auf Komplementfaktor C5a basierender Impfstoff
WO2014024026A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
EP2703483A1 (de) 2012-08-29 2014-03-05 Affiris AG PCSK9 Peptidimpfstoff
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
UY34506A (es) * 2012-12-10 2014-06-30 Fernando Amaury Ferreira Chiesa Adyuvante de vacunación, preparación y vacunas que lo contienen
WO2014140894A2 (en) 2013-03-15 2014-09-18 Bioven 3 Limited Self-assembling synthetic proteins
ES2924914T3 (es) 2013-03-15 2022-10-11 Glaxosmithkline Biologicals Sa Vacuna contra rinovirus humano
AR095962A1 (es) 2013-04-01 2015-11-25 Moreinx Ab Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
US8957047B2 (en) 2013-04-18 2015-02-17 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3030260A1 (de) 2013-08-05 2016-06-15 GlaxoSmithKline Biologicals S.A. Immunogene kombinationszusammensetzungen
JP6306700B2 (ja) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
WO2015071763A2 (en) 2013-11-15 2015-05-21 Oslo Universitetssykehus Hf Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
AU2014373928C1 (en) 2013-12-31 2020-12-17 Access To Advanced Health Institute Single vial vaccine formulations
EP3107568B1 (de) 2014-02-20 2024-03-27 Vaxart, Inc. Formulierungen für kleine intestinale verabreichung
JP6664338B2 (ja) 2014-06-13 2020-03-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組合せ物
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
WO2016011386A1 (en) 2014-07-18 2016-01-21 University Of Washington Cancer vaccine compositions and methods of use thereof
US11083788B2 (en) 2014-10-10 2021-08-10 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
MA40920A (fr) 2014-11-07 2017-09-12 Takeda Vaccines Inc Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
CA2977493C (en) 2015-03-03 2023-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Display platform from bacterial spore coat proteins
US10647964B2 (en) 2015-03-05 2020-05-12 Northwestern University Non-neuroinvasive viruses and uses thereof
CA2988761A1 (en) 2015-06-12 2016-12-15 Vaxart, Inc. Formulations for small intestinal delivery of rsv and norovirus antigens
IL257800B2 (en) 2015-09-03 2023-11-01 Novavax Inc Immune compositions with improved stability and immunogenicity
EP3138579A1 (de) 2015-09-05 2017-03-08 Biomay Ag Fusionsprotein zur behandlung einer infektion durch einen hepatitis-b-virus
CA3004498A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
CA3004482A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CN108350052A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
KR20180127320A (ko) 2016-03-14 2018-11-28 유니버시티에트 이 오슬로 변경된 FcRn 결합을 갖는 조작된 면역글로불린
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
EP3471761A2 (de) 2016-06-21 2019-04-24 University Of Oslo Hla-bindende impfstoffeinheiten und verwendungen davon
WO2018037045A1 (en) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
EP3295956A1 (de) 2016-09-20 2018-03-21 Biomay Ag Polypeptidkonstrukt mit fragmenten von allergenen
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
US10695424B2 (en) 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
EP3554538A2 (de) 2016-12-16 2019-10-23 Institute for Research in Biomedicine Neuartige rekombinante rsv-f-präfusionsproteine und verwendungen davon
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CA3066020A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
AU2018304957A1 (en) 2017-07-18 2020-02-13 In3Bio Ltd Synthetic proteins and therapeutic uses thereof
US20210069319A1 (en) 2017-09-07 2021-03-11 University Of Oslo Vaccine molecules
US20220118076A1 (en) 2017-09-07 2022-04-21 University Of Oslo Vaccine molecules
AU2018330165A1 (en) 2017-09-08 2020-04-02 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use
JP2020533354A (ja) 2017-09-13 2020-11-19 サノフィ・パスツールＳａｎｏｆｉ Ｐａｓｔｅｕｒ ヒトサイトメガロウイルス免疫原性組成物
AU2018359558C1 (en) 2017-11-03 2022-09-22 Takeda Vaccines, Inc. Method for inactivating Zika virus and for determining the completeness of inactivation
BR112020010635A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. extração de saponina
EP3717001A1 (de) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponinreinigung
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
IL305911A (en) 2018-03-19 2023-11-01 Novavax Inc Multifunctional nanoparticle vaccines for influenza
EP3569612A1 (de) 2018-05-18 2019-11-20 Biomay Ag Behandlung und prävention von hausstaubmilbenallergien
CN112638936A (zh) 2018-06-12 2021-04-09 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
EP3581201A1 (de) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptide und verwendungen davon
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
US11547672B2 (en) 2018-09-14 2023-01-10 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
WO2020128012A1 (en) 2018-12-21 2020-06-25 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
JP2022524007A (ja) 2019-03-05 2022-04-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｂ型肝炎免疫化レジメンおよび組成物
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
KR20220125149A (ko) 2019-05-25 2022-09-14 액세스 투 어드밴스드 헬스 인스티튜트 애주번트 백신 에멀션을 분무 건조시키기 위한 조성물 및 방법
JP2022539067A (ja) 2019-06-25 2022-09-07 イン３バイオ・リミテッド 安定化キメラ合成タンパク質及びその治療的使用
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
US20230201334A1 (en) 2019-07-24 2023-06-29 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
WO2021097347A1 (en) 2019-11-15 2021-05-20 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP4255919A2 (de) 2020-12-02 2023-10-11 GlaxoSmithKline Biologicals S.A. Donorstrang-komplementierte fimh
CN117320745A (zh) 2021-03-30 2023-12-29 维拉瓦克斯股份公司 Sars-cov-2亚单位疫苗
EP4313132A1 (de) 2021-03-31 2024-02-07 Vib Vzw Impfstoffzusammensetzungen für trypanosomatide
WO2023046898A1 (en) 2021-09-23 2023-03-30 Viravaxx AG Hbv vaccine inducing pres-specific neutralizing antibodies
WO2023114727A1 (en) 2021-12-13 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacteriophage lambda-vaccine system
US20230190920A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54132218A (en) * 1978-04-01 1979-10-15 Toyo Soda Mfg Co Ltd Separation of saponin constituents
FR2456116A1 (fr) 1979-05-11 1980-12-05 Sarget Lab Nouvelle saponine triterpenique derivee de la caulophyllogenine et ses applications therapeutiques
DE3040246C2 (de) * 1979-10-29 1985-01-10 Osaka Chemical Laboratory Co., Ltd., Osaka Sojasaponine A↓1↓ und A↓2↓ und ihre Verwendung
JPS617286A (ja) * 1984-06-22 1986-01-13 Kishimoto Sangyo Kk 単離サポニン製造方法

Also Published As

Publication number Publication date
EP0362279A4 (de) 1990-05-14
ATE116993T1 (de) 1995-01-15
DK602989A (da) 1989-11-29
EP0362279B1 (de) 1995-01-11
JP2731563B2 (ja) 1998-03-25
AU1934088A (en) 1988-12-21
DE3852761D1 (de) 1995-02-23
EP0362279B2 (de) 1999-11-03
DE3852761T2 (de) 1995-09-07
CA1331443C (en) 1994-08-16
DK602989D0 (da) 1989-11-29
EP0362279A1 (de) 1990-04-11
WO1988009336A1 (en) 1988-12-01
AU616670B2 (en) 1991-11-07
DK175739B1 (da) 2005-02-07
JPH02504266A (ja) 1990-12-06

Similar Documents

Publication Publication Date Title
DE3852761D1 (de) Saponin-hilfsmittel.
FI73995B (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla 6,11-dihydro-dibenso-/b,e/-tiepin-11-n-alkyl- norskopinetrar.
GB2303855B (en) Helicobacter pylori antigenic protein preparation and immunoassays
ES2174837T3 (es) Conjugados de saponina-antigeno y su utilizacion.
DE69118389D1 (de) Verbesserte vakzinzusammensetzung
IT8920207A0 (it) Procedimento per la preparazione di perfluoropolieteri perossidici.
DK173883D0 (da) Substituerede 8-phenylxanthiner
DE3875300D1 (de) Turbo-verbundmaschine.
DE69033745T2 (de) Oberflächenaktive zusammensetzungen und verfahren
ZA817896B (en) Novel d-homosteroids
PT789590E (pt) Imunopotenciacao induzida por quitosano
DK0597838T3 (da) Vaccinesammensætninger
AU539847B2 (en) 3,4,5-trihydroxypiperidine compounds
FI800350A (fi) Dehydropeptider foerfarande foer framstaellning av dessa samt anvaendningen av dessa som laekemedel
DE3750642D1 (de) Verfahren und Zusammensetzungen betreffend regressions-assoziierte Antigene.
IT8049346A0 (it) Composizione antigene relativo vaccino e procedimento di produzione
DE3776488D1 (de)
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: AQUILA BIOPHARMACEUTICALS, INC., WORCESTER, MASS.,

8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: ANTIGENICS INC., FRAMINGHAM, MASS., US